Literature DB >> 9700708

Peripheral and central motor conduction in amyotrophic lateral sclerosis.

K R Mills1, K A Nithi.   

Abstract

Conventional peripheral motor conduction studies and transcranial magnetic stimulation (TMS) studies, to measure central motor conduction time (CMCT), to the first dorsal interosseous muscle (FDI) were performed on 65 patients with amyotrophic lateral sclerosis (ALS). The hands of each patient were classified into one of four groups depending on the presence of physical signs of lower motor neurone (LMN) and/or upper motor neurone (UMN) involvement. Statistical analysis was made of the results from patients compared with previously established normal values and with those from a control group of 53 normal subjects. Results between the four groups of patients were compared in order to assess any correlation between neurophysiological findings and physical signs. A reduction in the amplitude of compound muscle action potentials (CMAP), prolongation of distal motor latency (DML) and F wave latency were found in 36%, 34% and 19% of hands respectively. These abnormalities were more common in hands with LMN signs. In nine hands, prolongation of DML occurred in the absence of muscle wasting or weakness. CMCT abnormalities were present in 17% of patients with ALS but did not appear to correlate with physical signs.

Entities:  

Mesh:

Year:  1998        PMID: 9700708     DOI: 10.1016/s0022-510x(98)00148-8

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

1.  Optimising the detection of upper motor neuron function dysfunction in amyotrophic lateral sclerosis--a transcranial magnetic stimulation study.

Authors:  Abena D Osei-Lah; Kerry R Mills
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

2.  Evaluation of corticospinal excitability in cervical myelopathy, before and after surgery, with transcranial magnetic stimulation: a pilot study.

Authors:  Alessia Nicotra; Nicolas K K King; Maria Catley; Nigel Mendoza; Alison H McGregor; Paul H Strutton
Journal:  Eur Spine J       Date:  2012-11-07       Impact factor: 3.134

3.  Decreased thickness of primary motor cortex in primary lateral sclerosis.

Authors:  J A Butman; M K Floeter
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

4.  Upper motor neuron involvement in amyotrophic lateral sclerosis evaluated by triple stimulation technique and diffusion tensor MRI.

Authors:  Jasna Furtula; Birger Johnsen; Jesper Frandsen; Anders Rodell; Peter Broegger Christensen; Kirsten Pugdahl; Anders Fuglsang-Frederiksen
Journal:  J Neurol       Date:  2013-01-09       Impact factor: 4.849

Review 5.  Amyotrophic lateral sclerosis: objective upper motor neuron markers.

Authors:  Petra Kaufmann; Hiroshi Mitsumoto
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

6.  Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS.

Authors:  M R Turner; A D Osei-Lah; A Hammers; A Al-Chalabi; C E Shaw; P M Andersen; D J Brooks; P N Leigh; K R Mills
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

Review 7.  Electrodiagnosis in persons with amyotrophic lateral sclerosis.

Authors:  Nanette C Joyce; Gregory T Carter
Journal:  PM R       Date:  2013-03-21       Impact factor: 2.298

8.  Interpretation of electrodiagnostic findings in sporadic progressive muscular atrophy.

Authors:  J Visser; M de Visser; R M Van den Berg-Vos; L H Van den Berg; J H J Wokke; J M B V de Jong; H Franssen
Journal:  J Neurol       Date:  2008-05-19       Impact factor: 4.849

9.  Transcranial magnetic stimulation in ALS: utility of central motor conduction tests.

Authors:  A G Floyd; Q P Yu; P Piboolnurak; M X Tang; Y Fang; W A Smith; J Yim; L P Rowland; H Mitsumoto; S L Pullman
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

Review 10.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.